文献速递炎症性肠病

老年起病炎症性肠病患者启动各类药物的机会降低且手术风险增加:一项全国性队列研究

Patients with elderly onset inflammatory bowel disease have a decreased chance of initiation of all types of medications and increased risk of surgeries-A nationwide cohort study.
PubMed 文献 · Aliment Pharmacol Ther · 2023-04-20

基于丹麦登记数据的全国性队列研究纳入1995至2020年69,039例≥18岁新发炎症性肠病患者,分为老年起病(≥60岁,19,187例)与成人起病(49,852例)。老年患者1年内启动硫唑嘌呤、5-氨基水杨酸和生物制剂的校正风险比分别为0.44、0.77和0.29,5年内结果相似;老年患者手术风险升高,溃疡性结肠炎5年内aHR 1.39,克罗恩病1.13。

要点

  • 老年起病IBD患者启动硫唑嘌呤、5-氨基水杨酸和生物制剂的机会显著低于成人起病患者。
  • 老年患者药物持续性与成人相当,但停用糖皮质激素的机会降低。
  • 老年患者手术风险升高,溃疡性结肠炎5年内aHR 1.39,克罗恩病1.13。

核心结论

  • 老年起病IBD患者启动IBD药物的机会显著降低,原因可能并非疾病病程较轻。
  • 老年患者药物持续性与成人相当。
  • 临床医生应仔细考虑是否在老年患者中未充分使用IBD特异性药物,并特别关注及时停用糖皮质激素。

研究设计与样本

  • 基于丹麦登记数据的全国性队列研究,纳入1995至2020年≥18岁新发IBD患者共69,039例。
  • 患者分为老年起病(≥60岁,19,187例)与成人起病(49,852例)两组。
  • 采用回归模型控制协变量,评估诊断后1年和5年内启动硫唑嘌呤、5-氨基水杨酸、生物制剂和糖皮质激素的情况及药物持续性,并检查1年和5年内手术。

主要发现

  • 老年患者1年内启动硫唑嘌呤、5-氨基水杨酸和生物制剂的校正风险比分别为0.44(95% CI 0.42-0.47)、0.77(95% CI 0.75-0.79)和0.29(95% CI 0.26-0.31),5年内结果相似。
  • 老年患者5年内硫唑嘌呤、5-氨基水杨酸和生物制剂的药物持续性未受损。
  • 老年患者1年和5年内停用糖皮质激素的校正风险比分别为0.80(95% CI 0.76-0.84)和0.77(95% CI 0.74-0.80)。
  • 老年患者手术风险升高:溃疡性结肠炎5年内aHR 1.39(95% CI 1.27-1.52),克罗恩病1.13(95% CI 1.04-1.23)。

临床怎么用

  • 作者认为,临床医生应仔细考虑是否在老年患者中未充分使用IBD特异性药物。
  • 作者认为,应特别关注及时停用糖皮质激素。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: In patients with elderly (≥60 years) onset inflammatory bowel disease (IBD), we studied initiation of medications, drug persistency and surgeries. DESIGN: A nationwide cohort study based on Danish registries, comprising incident IBD patients ≥18 years from 1995 to 2020 (N = 69,039). Patients were divided into elderly (N = 19,187) and adult onset (N = 49,852). Outcomes were initiation of thiopurines, 5-ASA, biologics and corticosteroids within 1 and 5 years after diagnosis, and for those who initiated medications, we estimated drug persistency. Surgeries were examined within 1 and 5 years. We used regression models controlling for covariates. RESULTS: In elderly patients, the adjusted hazard ratios (aHR) for initiating thiopurines, 5-ASA and biologics within 1 year were 0.44 (95% CI 0.42-0.47), 0.77 (95% CI 0.75-0.79) and 0.29 (95% CI 0.26-0.31) respectively. The results were similar within 5 years. In elderly patients, drug persistency for thiopurines, 5-ASA and biologics was not impaired within 5 years. The aHR of stopping steroids within 1 and 5 years were 0.80 (95% CI 0.76-0.84) and 0.77 (95% CI 0.74-0.80) respectively. The risk of surgeries was increased in the elderly patients (in ulcerative colitis, within 5 years, aHR 1.39 [95% CI 1.27-1.52], and in Crohn's disease 1.13 [95% CI 1.04-1.23]). CONCLUSION: We found significantly low chance of initiation of IBD medications in elderly patients, the reason may not be due to mild disease course. In elderly patients, drug persistency was comparable to adults. Clinicians should carefully consider whether they underuse IBD-specific medications in elderly patients, and special attention should be applied to timely discontinuation of corticosteroids.

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Nørgård BM, Zegers FD, Knudsen T, et al. Patients with elderly onset inflammatory bowel disease have a decreased chance of initiation of all types of medications and increased risk of surgeries-A nationwide cohort study. Aliment Pharmacol Ther. 2023. PMID: 37078376. doi:10.1111/apt.17520

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。